


# Exenatide QW significantly improved HbA1c reductions vs exenatide BID at 30 weeks<sup>1</sup>



In a second study comparing exenatide QW to exenatide BID in 252 patients with type 2 diabetes the fall in HbA<sub>1c</sub> at 24 weeks was -1.6% (-17 mmol/mol) and -0.9% (-10 mmol/mol) respectively resulting in a treatment difference of -0.7% (95% CI -0.9 to -0.4; p<0.0001)<sup>2</sup>

1. Drucker DJ et al. *Lancet*. 2008;372:1240-1250  
 2. Blevins T et al. *J Clin Endocrinol Metab* 2011; 96; 1301-1310